Royal United Hospitals Bath Nhs Foundation Trust

Royal United Hospitals Bath Join Study on Milvexian for Stroke Risk Reduction

- The Royal United Hospitals (RUH) Bath NHS Foundation Trust is participating in the Librexia study to evaluate Milvexian's efficacy in reducing recurrent ischaemic stroke risk. - Participants, aged 40 and above, who have experienced an ischaemic stroke or transient ischaemic attack within 48 hours are eligible for the trial. - Milvexian, an anticoagulant, is being tested against a placebo, alongside standard medications, to assess its impact on blood clot formation and stroke prevention. - The study involves regular assessments at the RUH, including blood tests and liver/kidney function tests, every 13 weeks for participating patients.